[1]
S. T. Stoffel, “Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study”, Swiss Med Wkly, vol. 151, no. 0910, p. w20464, Mar. 2021.